BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27754993)

  • 1. YM155 inhibits topoisomerase function.
    Hong M; Ren MQ; Silva J; Paul A; Wilson WD; Schroeder C; Weinberger P; Janik J; Hao Z
    Anticancer Drugs; 2017 Feb; 28(2):142-152. PubMed ID: 27754993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mechanism of radiosensitization by YM155, a novel small molecule inhibitor of survivin expression, is associated with DNA damage repair.
    Hu S; Fu S; Xu X; Chen L; Xu J; Li B; Qu Y; Yu H; Lu S; Li W
    Cell Physiol Biochem; 2015; 37(3):1219-30. PubMed ID: 26418254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YM155 and BIRC5 downregulation induce genomic instability via autophagy-mediated ROS production and inhibition in DNA repair.
    Cheng SM; Lin TY; Chang YC; Lin IW; Leung E; Cheung CHA
    Pharmacol Res; 2021 Apr; 166():105474. PubMed ID: 33549731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
    Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
    Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair.
    Qin Q; Cheng H; Lu J; Zhan L; Zheng J; Cai J; Yang X; Xu L; Zhu H; Zhang C; Liu J; Ma J; Zhang X; Dai S; Sun X
    J Hematol Oncol; 2014 Aug; 7():62. PubMed ID: 25139395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
    Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
    Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
    Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
    Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinone-Based Antitumor Agent Sepantronium Bromide (YM155) Causes Oxygen-Independent Redox-Activated Oxidative DNA Damage.
    Wani TH; Surendran S; Jana A; Chakrabarty A; Chowdhury G
    Chem Res Toxicol; 2018 Jul; 31(7):612-618. PubMed ID: 29897742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dioxonaphthoimidazoliums AB1 and YM155 disrupt phosphorylation of p50 in the NF-κB pathway.
    Ho SH; Ali A; Chin TM; Go ML
    Oncotarget; 2016 Mar; 7(10):11625-36. PubMed ID: 26872379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells.
    Xu Q; Mackay RP; Xiao AY; Copland JA; Weinberger PM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [
    Mitsuoka K; Kita A; Murakami Y; Shirasuna K; Noda A; Yamanaka K; Kaneko N; Miyoshi S
    Nucl Med Biol; 2018; 64-65():41-46. PubMed ID: 30041149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative, DNA intercalation and redox cycling activities of dioxonaphtho[2,3-d]imidazolium analogs of YM155: A structure-activity relationship study.
    Ho SH; Sim MY; Yee WL; Yang T; Yuen SP; Go ML
    Eur J Med Chem; 2015 Nov; 104():42-56. PubMed ID: 26433618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
    Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
    Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ym155 localizes to the mitochondria leading to mitochondria dysfunction and activation of AMPK that inhibits BMP signaling in lung cancer cells.
    Mondal A; Jia D; Bhatt V; Akel M; Roberge J; Guo JY; Langenfeld J
    Sci Rep; 2022 Jul; 12(1):13135. PubMed ID: 35908087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
    Wagner V; Hose D; Seckinger A; Weiz L; Meißner T; Rème T; Breitkreutz I; Podar K; Ho AD; Goldschmidt H; Krämer A; Klein B; Raab MS
    Oncotarget; 2014 Nov; 5(21):10237-50. PubMed ID: 25296978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
    Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
    Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.
    Mir R; Stanzani E; Martinez-Soler F; Villanueva A; Vidal A; Condom E; Ponce J; Gil J; Tortosa A; Giménez-Bonafé P
    Gynecol Oncol; 2014 Jan; 132(1):211-20. PubMed ID: 24262875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of Survivin Pathways by YM155 Inhibits Cell Death and Invasion in Oral Squamous Cell Carcinoma Cells.
    Zhang W; Liu Y; Li YF; Yue Y; Yang X; Peng L
    Cell Physiol Biochem; 2016; 38(6):2426-37. PubMed ID: 27287458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
    Shakushiro K; Kawano H; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
    Pharm Res; 2015 Jan; 32(1):238-47. PubMed ID: 25033765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.